183 results on '"PELLACANI, ANDREA"'
Search Results
2. Booster immunization with a fractional dose of Prevnar 13 affects cell-mediated immune response but not humoral immunity in CD-1 mice
3. Supplementary Tables S1-S2 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
4. Supplementary Table S5 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
5. Supplementary Figure S2 from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
6. Data from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
7. Supplementary S3 A-B from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
8. Supplementary Data from MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
9. Influence of Porosity on R-Curve Behaviour of Tetragonal Stabilized Zirconia
10. Centroid regression using CNN-based Image Processing Algorithm with application to a binary asteroid system
11. Influence of porosity on R-curve behaviour of tetragonal stabilized zirconia
12. Mo1668 SAFETY AND EFFICACY OF VELUSETRAG IN CHRONIC INTESTINAL PSEUDO-OBSTRUCTION: PHASE II PROOF-OF-CONCEPT STUDY
13. SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial
14. AFC HERA simulated images along COP trajectory for Ground Navigation support and Dimorphos 3D reconstruction
15. Abstract 1170: MEN1112/OBT357, a first-in-class humanized de-fucosylated monoclonal antibody targeting CD157 positive cells in acute myeloid leukemia and myelodysplastic syndrome
16. Abstract 1376: Dosing frequency/PD/efficacy relationship of MEN1611 in HER2 amplified, PIK3CA mutated, and refractory to Trastuzumab xenograft model of breast cancer
17. Updated results from DIAMOND-01 (CLI24-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.
18. Abstract PS18-13: Men1611 is a pi3k α/β selective and δ sparing inhibitor with long-lasting antitumor activity in different genetic backgrounds of pik3ca mutant breast cancer models
19. SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial
20. Didymos images´ simulation for 3D reconstruction within HERA project
21. Plasma bradykinin in angio-oedema
22. SERUM LEVELS OF OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-κB LIGAND AS MARKERS OF PERIPROSTHETIC OSTEOLYSIS
23. Semi-autonomous attitude guidance using relative navigation based on line of sight measurements – Aim scenario
24. Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1β in vascular smooth muscle cells
25. Design, Development, Validation and Verification of GNC technologies
26. HERA vision based GNC and autonomy
27. CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia
28. First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia
29. Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001
30. MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
31. B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer.
32. CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial carcinoma.
33. CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia.
34. ESE-1 Is a Novel Transcriptional Mediator of Inflammation That Interacts with NF-κB to Regulate the Inducible Nitric-oxide Synthase Gene
35. Down-regulation of High Mobility Group-I(Y) Protein Contributes to the Inhibition of Nitric-oxide Synthase 2 by Transforming Growth Factor-β1
36. Transforming Growth Factor-β1 Inhibition of Macrophage Activation Is Mediated via Smad3
37. Thioredoxin Facilitates the Induction of Heme Oxygenase-1 in Response to Inflammatory Mediators
38. Abstract 2145: The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment
39. Abstract 2160: MEN1611, a novel α-selective PI3K inhibitor in solid tumors
40. CD205-Shuttle study: A first-in-human trial of MEN1309/OBT076 an ADC targeting CD205 in solid tumor and NHL.
41. High Mobility Group-I(Y) Protein Facilitates Nuclear Factor-κB Binding and Transactivation of the Inducible Nitric-oxide Synthase Promoter/Enhancer
42. Induction of High Mobility Group-I(Y) Protein by Endotoxin and Interleukin-1β in Vascular Smooth Muscle Cells: ROLE IN ACTIVATION OF INDUCIBLE NITRIC OXIDE SYNTHASE
43. Abstract B188: DNA topoisomerase-mediated transcription-replication conflicts cause DNA damage by a transient increase of R loops and proteasome activity
44. Immunohistochemical evaluation of bone metastases
45. CD205, a target antigen for a novel antibody drug conjugate (ADC): Evaluation of antigen expression on non-Hodgkin lymphoma (NHL).
46. Is wear debris responsible for failure in alumina-on-alumina implants?
47. The serum level of TRACP 5b in osteosarcoma patients is associated with an aggressive behaviour
48. Cytokeratin expression and prognosis of skeletal metastases
49. Elevated serum activity of TRACP5b in osteosarcoma patients is associated with an aggressive phenotype
50. serum level of osteoprotegerin (OPG) and 'receptor activator of nuclear factor ligand (RANKL) in patients with total hip prostheses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.